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INTRODUCTION
Th e migration of leukocytes from the vascular compart-
ment into the infl ammation area requires a series of complex 
interactions between leukocytes and endothelium. Th ese 
intercellular interactions depend on the presence of the che-
moattractant gradient created by a large family of molecules 
called chemokines (chemotactic cytokines), along with the cell 
adhesion molecules expressed on the surfaces of endothelial 
cells and leukocytes [1]. Under the normal physiological con-
ditions, chemokines selectively divert leukocyte subtypes to all 
tissues and organs [2]. Ulcerative colitis (UC) and Crohn’s dis-
ease (CD) are two chronic infl ammatory bowel diseases (IBD), 
characterized by the altered levels and types of chemokines 
resulting in improper leukocyte aggregation in the target tissue.
To date, more than 40 chemokines have been discovered. 
So far, the only member of the identifi ed CX3C chemokine 
family is fractalkine (FKN-CX3CL1). FKN shows dual charac-
teristics, acting both as a chemokine and as an adhesion mol-
ecule [3,4].
FKN is expressed during an infl ammatory process and 
therefore takes place in the pathogenesis of numerous infl am-
matory conditions including cardiovascular, renal, rheuma-
tologic and allergic diseases [3,5-7]. FKN expression on the 
endothelial and epithelial cells of the human bowel mucosa 
questioned the role of FKN regulation in mucosal immune 
response in IBD [8,9].
CX3CR1 is the specifi c receptor of FKN. CX3CR1 is 
expressed on the surface of CD4+ and CD8+ T cells, CD14+ 
monocytes and macrophages, and CD16+ NK cells [4,10]. 
CX3CR1 is highly expressed on the cytotoxic T-lymphocytes. 
CX3CR1-expressing cells are bound to FKN with high affi  nity 
regardless of the presence of endothelial adhesion molecules 
such as selectin and integrin. To date, several gene variations 
have been identifi ed on the CX3CR1 encoding gene.
Among these, V249I (rs3732379) and T280M (rs3732378) 
polymorphisms are more common than the other genetic 
variations. Th ese polymorphisms are implicated in athero-
sclerosis, coronary artery disease, and susceptibility to HIV 
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ABSTRACT
Fractalkine (CX3C), a chemokine expressed by epithelial cells within normal and infl amed colorectal mucosa, induces leukocyte adhesion and 
migration via fractalkine receptor. Th e aim of this study was to investigate two single nucleotide polymorphisms of the fractalkine receptor 
gene as a risk factor both for the development and clinical fi ndings of ulcerative colitis. In this study, 51 patients with ulcerative colitis (UC) 
and 80 controls were recruited. Genotypes of fractalkine receptorc.745G>A (V249I) and c.839C>T (T280M) polymorphisms were identifi ed 
by restriction fragment length polymorphism analyses after polymerase chain reaction.Genotype distribution and allele frequencies of V249I 
and T280M were not statistically signifi cantly diff erent between UC and control groups (p>0.05). No statistically signifi cant relationship was 
found between fractalkine receptor polymorphisms and clinical fi ndings of UC. We observed no signifi cant diff erence in fractalkine receptor 
polymorphism between patients and control group and no genotype-phenotype relation. Th erefore, we concluded that fractalkine receptor 
polymorphisms may not contribute to the molecular pathogenesis of UC.
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infection. Th ey also infl uence CD phenotype and localiza-
tion [11-13].
In this study, we aimed to determine the CX3CR1 poly-
morphisms and their correlation with clinical fi ndings in 
patients with UC.
MATERIALS AND METHODS
Study population
A total of 51 UC patients attending the Department of 
Gastroenterology and Hepatology, Baskent University Ankara 
Hospital, were enrolled in the study. Th e diagnosis of UC was 
made on the basis of previously defi ned clinical guidelines, 
according to endoscopic, radiologic and histopathological cri-
teria. Th ese criteria were also used as a tool for patient selec-
tion [14-17]. Patients with indeterminate colitis were excluded 
from the study. Control group was composed of 80 healthy 
subjects attending the gastroenterology outpatient clinic with 
dyspeptic complaints. Informed consent was obtained from 
all study participants.
Demographic data and medical history of patients (gen-
der, age, age at diagnosis, follow-up duration of the disease, 
localization of the colonic involvement and extraintestinal 
involvement (musculoskeletal system, skin, eye, hepatobiliary 
system)) were recorded.
Genotyping
Venous blood sample was obtained from each par-
ticipant. Genomic DNA was extracted using commer-
cially available kit (High Pure PCR Template Kit, Roche 
Diagnostics GmbH, Mannheim, Germany). Genotypes were 
determined by polymerase chain reaction (PCR)–restric-
tion fragment length polymorphism (RFLP) method. Two 
regions, each of which contained a single nucleotide poly-
morphism (SNP) site of the fractalkine receptor gene, were 
amplifi ed. Primers for the PCR amplifi cation were forward: 
5’AGAATCATCCAGACGCTGTTTTCC3’, and reverse: 
5’CACAGGACAGCCAGGCATTTCC3’. Th e size of ampli-
con, restriction endonuclease, and predicted fragment lengths 
are shown in Table 1. After restriction enzyme digestion geno-
types were evaluated.
CX3CR1 polymorphism genotyping and clinical 
correlations
Th e association between V249I and T280M polymor-
phisms with the clinical fi ndings (gender, age, age at diag-
nosis and follow-up duration of the disease, location of the 
intestinal involvement, intestinal involvement type, perianal 
involvement and extraintestinal involvement) in patients was 
examined.
Statistical methods
Independent two-sample t test was used to compare two 
groups and one-way analysis of variance was used for compar-
ison of more than two groups. All analyses had a confi dence 
interval of 95. Variants in the analyses were grouped among 
themselves according to their characteristics. Diff erence in 
allele frequencies of CX3CR1 polymorphisms between IBD 
patients and the control group was determined using universe 
ratio signifi cance test. Th e value of p<0.05 was considered 
statistically signifi cant. Statistical analyses were performed in 
SPSS 17.0 and MINITAB 13.0 statistical software programs 
(SPSS Inc., Chicago, IL).
RESULTS
Study group consisted of 30  males (58.8 ) and 
21  females. Mean age of patients was 45.9±13.4.Th e mean 
age was39.4±12.7  years at the time of diagnosis and patients 
were followed-up during the period from 1 to 37 years (mean 
6.5±6.7).Twenty-four patients had proctitis or proctosigmoid 
involvement, while nine (17.6) patients had extraintestinal 
involvement. Th e most common extraintestinal involvement 
was the musculoskeletal system (arthritis, ankylosing spon-
dylitis, other spondyloarthropathies). Other extraintestinal 
involvements were as follows: one patient with aphthous 
stomatitis, one patient with dry eye, while hepatobiliary tract 
was aff ected in two patients (primary sclerosing cholangi-
tis). Clinical and demographic characteristics of patients are 
shown in Table 2.
Th e distribution of the c.745G>A (V249I) and c.839C>T 
(T280M) genotypes and the allele frequencies were not dif-
ferent between the patients and controls. For V249I polymor-
phism 22  (32.8) patients were heterozygous, while 3  (4.5) 
patients were homozygous. A total of 12 (17.9) patients were 
heterozygous for T280M polymorphism.
For both polymorphisms (V249I and T280M), no statis-
tically signifi cant diff erence was observed for gender (p=0.16 
and p=0.5 respectively), age (p=0.8 and p=0.1 respectively), age 
at diagnosis (p=0.8 and p=0.07 respectively), follow-up dura-
tion of the disease(p=0.9 and p=0.8 respectively),localization 
of colonic involvement(p=0.9 and p=0.2 respectively), and 
TABLE 1. Amplicon size, restriction endonuclease and fragment 
lengths
Site Amplicon size
Restriction 
endonuclease
Fragment 
lengths (bp)
V249I 311 ACLI 107-204 V/V
107-204-311 V/I
311I/I
T280M 311 BSMBI 75-118 T/T
75-118-193 T/M
118-193 M/M
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extraintestinal involvement (p=0.7 and p=0.2, respectively).
Genotype distributions and allele frequencies of FKN 
receptor polymorphisms were shown in Table 3 and Table 4, 
respectively.
DISCUSSION
Both chemokines and their receptors participate in the 
pathogenesis of infl ammatory disease by navigating circu-
lating leukocytes and T cells to infl ammatory sites. At the 
molecular level, they orchestrate tissue- and cell type-specifi c 
traffi  cking as well as retention of leukocytes. Previous studies 
showed the role of FKN and its receptor system in the devel-
opment of infl ammatory diseases. Rapid recruitment and 
inappropriate retention of leukocytes, particularly T-cells at 
the site of infl ammation is a sign of chronic infl ammatory dis-
orders such as CD and UC [18,19].
Due to an increased release of FKN from intraepithelial 
cells, there is an increased number of CX3CR1+ T cells both in 
peripheral blood and intestinal lamina propria of IBD patients. 
Increased FKN production in the mucosa causes migration 
of a large number of CX3CR1+ leukocytes to the infl amma-
tion site [8,11,20,21]. It was also demonstrated that the level of 
expression of FKN receptors is much higher on Th 1  cells in 
comparison to Th 2 cells as a response to FKN. [22]. Recently, 
two common SNPs, V249I and T280M, were identifi ed in 
the FKN receptor encoding gene. Both polymorphisms are 
located in the transmembrane domains of the receptor, caus-
ing a reduction in cell adhesion and possibly leading to the 
decreased signaling and chemotaxis [23,24].
Although various data about the genotype-phenotype 
relationship between FKN receptor polymorphisms and 
CD have been reported, there are no reports about this rela-
tionship for UC. In a study conducted on the sample of CD 
patients, Brand et al. determined that 33 of participants were 
heterozygous, while 8.9 were homozygous for V249I poly-
morphism. On the other hand, these percentages for T280M 
polymorphism were 23.3 and 4.4, respectively. Authors 
observed that intestinal stenosis and ileocolonic involvement 
occurred more frequently in patients with T280M and V249I 
homozygous polymorphism than in heterozygous patients 
and wild type. Ileal involvement (89 ileocolonic, 11 ileal) 
was also observed in T280M homozygous patients [11].
In another study that was conducted on CD patients, 
Sabate et al found that heterozygosity and homozygosity for 
V249I polymorphism were 37.4 and 8.8, while the frequency 
for T280M polymorphism was18.1 and 1.3, respectively. In 
this study, T280M homozygous genotype was observed in 
three patients, with two of them having been diagnosed with 
stenosis. V249I polymorphism was detected in patients with 
fi brostenosis [13].
In contrast to previous studies exploring the role of FKN 
in CD, in our study we aimed to determine FKN receptor 
polymorphism frequency and its correlation with clinical 
presentation in UC patients. We found 5.9 homozygous and 
43.1 heterozygous patients for the V249I polymorphism and 
23.5 heterozygous patients for the T280M polymorphism. 
Frequency distributions of both polymorphisms were similar 
to those in the control group (Table 3 and Table 4).
Our sub-group analyses revealed that neither V249I nor 
T280M polymorphisms were associated with clinical signs of 
UC.
So far, several hundreds of genes residing within the 163 
genetic risk loci have been identifi ed for IBD [25]. Although 
both CD and UC are infl ammatory bowel diseases that share 
some genetic susceptibility loci, there are actually some diff er-
ences [26]. Among these loci, 30 are CD-specifi c and 23 are 
UC-specifi c, whereas 110 are associated with both disease 
phenotypes [27]. According to this genetic background, reg-
ulation of mucosal immune cells is diff erent in UC from CD. 
Th e molecular mechanism of CD depends on the Th 1/Th 17 
balance [28,29]. FKN receptor is particularly expressed on 
TABLE  2. Demographic and clinical characteristics of the study 
population
Female n (%) 21 (41.2)
Male 30 (58.8)
Age (year) - mean±SD 45.9±13.4
Age at diagnosis (year) - mean±SD 39.4±12.7
Disease duration (year) - mean±SD 6.5±6.7 (min-max: 1-37 years)
Localization n (%)
Proctitis/proctosigmoiditis 24 (47%)
Left sided colitis 4 (7.8%)
Extensive colitis 17 (33.4%)
Pancolitis 6 (11.8%)
Extraintestinal manifestations n (%) 9 (17.6)
TABLE 3. The CX3CR1 polymorphism distribution in UC patients
Genotypes UC (n=51) Control (n=80) p
V249I (n (%))
VV
VI
II
26 (51.0)
22 (43.1)
3 (5.9)
49 (61.25)
28 (35.0)
3 (3.75)
0.491
T280M (n (%))
TT
TM
MM
39 (76.5)
12 (23.5)
-
52 (65.0)
28 (35.0)
-
0.179
TABLE 4. Allele frequencies of V249I and T280M polymorphisms 
in patient and control subjects
Genotypes UC (n=51) Control (n=80) p
V249I (n (%))
V
I
74 (72.55)
28 (27.45)
126 (78.75)
34 (21.25)
0.76
0.23
T280M (n (%))
T
M
90 (88.24)
12 (11.76)
132 (82.50)
28 (17.50)
0.84
0.11
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Th 1 cells. However, it has been shown that molecular mecha-
nisms of UC mainly depend on Th 2 cells [22,30]. As indicated 
by Th omson et al, genetic factors seem to be somewhat less 
signifi cant for UC than they are for CD [28]. Our results are 
consistent with the results of the study published by Th omson 
et al. According to these data, clinical signs of UC may not be 
related to FKN receptor polymorphism.
CONCLUSION
In conclusion, in this study we tried to determine the 
possible involvement of FKN receptor polymorphism in UC 
pathogenesis and its relation with clinical outcomes. So far, no 
studies on the relationship between FKN receptor polymor-
phisms and clinical signs of UC have been published. In our 
study, we found that FKN receptor polymorphism and gen-
otype-phenotype relation is not statistically signifi cant in UC 
patients. Th erefore, these polymorphisms of FKN may not 
contribute to the molecular pathogenesis of UC. However, 
limited number of patients enrolled to this study may be the 
major limitation of this study. Th erefore, further studies with 
larger groups are required in order to determine the precise 
role of the FKN receptor polymorphisms in disease pathogen-
esis and its relation to clinical outcomes in patients with UC.
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